Belinostat + Azacitidine/Pralatrexate for T-Cell Lymphoma

This trial aims to determine the safest and most effective way to use a combination of azacitidine, belinostat, and pralatrexate to treat certain types of T-cell lymphomas. These cancers affect a specific kind of white blood cell, and the trial targets those whose cancer has returned or did not respond to previous treatments. Participants are divided into two main groups: one group receives azacitidine and belinostat, while the other receives pralatrexate and belinostat. This trial suits individuals who have already tried at least one treatment for their T-cell lymphoma and need another option. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new combination therapy.

Research has shown that azacitidine and belinostat, both FDA-approved for other uses, have a known safety record in humans. Azacitidine stops cancer cells from making DNA, potentially aiding in their destruction. Belinostat blocks certain enzymes, which may prevent cancer cells from dividing and growing. It also treats peripheral T-cell lymphoma (PTCL), a type of blood cancer.

Studies on pralatrexate, another FDA-approved drug for PTCL, have indicated it can cause side effects like mouth sores and low blood cell counts. Researchers are exploring its use with belinostat to determine if this combination might improve outcomes for certain T-cell lymphomas.

Researchers are excited about the treatments for T-cell lymphoma in this trial because they combine belinostat, a histone deacetylase inhibitor, with either azacitidine or pralatrexate, offering a fresh approach. Unlike traditional chemotherapy, belinostat works by modifying the expression of genes that control cell growth, potentially making cancer cells more susceptible to treatment. Azacitidine is known for its role in altering DNA methylation, while pralatrexate targets folic acid metabolism, both adding unique mechanisms to the mix. This combination aims to tackle the cancer cells from multiple angles, which could enhance effectiveness and overcome resistance found in standard treatments like CHOP chemotherapy.

Research has shown that combining belinostat with azacitidine may help treat T-cell lymphomas. In this trial, participants in Arm A will receive this combination. Studies have found that azacitidine alone can lead to a complete response in 50% of patients, meaning half showed no signs of cancer afterward. Belinostat by itself has helped about 25% of patients with peripheral T-cell lymphoma by reducing the size or spread of their cancer.